History of Adjuvant Therapy

  • Pinuccia Valagussa
Part of the Cancer Treatment and Research book series (CTAR, volume 151)

Breast cancer is a significant public health problem in virtually all industrialized societies. In many developed countries it is the most common life-threatening malignancy and the second most frequent cause of cancer-related mortality. After peaking in the 1990s, and despite a gradual increase in incidence [1], the overall mortality for breast cancer has been declining in the United States and in some European countries [1, 2].


Breast Cancer Adjuvant Trial Ovarian Ablation Improve Breast Cancer Outcome Time Reverse Transcription Polymerase Chain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jemal A, Siegel R, Ward E. Cancer statistics. CA Cancer J Clin. 2006;56:106–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Peto R, Boreham J, Clarke M, et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet. 2000;355:1822.PubMedCrossRefGoogle Scholar
  3. 3.
    Kinne D. Primary treatment of breast cancer. In: Harris JR, Helman S, Henderson IC, et al., eds. Breast Diseases. Philadelphia, PA, Lippincott; 1991:347–73.Google Scholar
  4. 4.
    Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46:1–19.PubMedCrossRefGoogle Scholar
  5. 5.
    Fisher B, Fisher ER. The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg Gynecol Obstet. 1966;122:791–98.PubMedGoogle Scholar
  6. 6.
    Fisher B. The evolution of paradigms for the management of breast cancer: A personal perspective. Cancer Res. 1992;52:2371–83.PubMedGoogle Scholar
  7. 7.
    Skipper HE, Schabel FM Jr. Tumor stem cell heterogeneity: Implication with respect to the classification of cancers by chemotherapeutic effect. Cancer Treat Rep. 1984;68:43–61.PubMedGoogle Scholar
  8. 8.
    Griswold DP Jr. Body burden of cancer in relationship to therapeutic outcome: Consideration of preclinical evidence. Cancer Treat Rep. 1986;70:81–6.PubMedGoogle Scholar
  9. 9.
    Martin DS, Fugman RA, Stolfi RL, Hayworth PE. Solid tumor animal model therapeutically predictive for human breast cancer. Cancer Chemother Rep. 1975;5:89–109.Google Scholar
  10. 10.
    Henderson IC. Adjuvant endocrine therapy. In: J Allegra, ed. Management of Breast Cancer through Endocrine Therapies. Amsterdam: Excerpta Medica; 1984:38–57.Google Scholar
  11. 11.
    Pritchard KI. Current status of adjuvant endocrine therapy for resectable breast cancer. Semin Oncol. 1987;14:23–33.PubMedGoogle Scholar
  12. 12.
    Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet. 1996;348:1189–96.CrossRefGoogle Scholar
  13. 13.
    Nolvadex Adjuvant trial organization. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis of six years. Lancet. 1985;1:836–40.Google Scholar
  14. 14.
    Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRefGoogle Scholar
  15. 15.
    Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:456–62.CrossRefGoogle Scholar
  16. 16.
    Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years. J Natl Cancer Inst. 2001:93:456–62.PubMedCrossRefGoogle Scholar
  17. 17.
    Peto R, Davies C and the ATLAS investigators. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): International randomized trials of 10 versus 5 years of adjuvant tamoxifen among 11,500 women: Preliminary results. In: Program and Abstracts of the 30th Annual San Antonio Breast Cancer Symposium; San Antonio, Texas (abstract 48).Google Scholar
  18. 18.
    Gray RG, Rea DW, Handley K, et al. aTTom adjuvant Tamoxifen – To offer more?: Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer – preliminary results. Proc Am Soc Clin Oncol, 26, 2008 (abstract 513).Google Scholar
  19. 19.
    Osborne CK. Effects of estrogen and antiestrogens on cell proliferation. In: Osborne CK, Ed. Endocrine Treatment in Breast and Prostate Cancer. Boston, MA: Kluwer; 1988:11–129.CrossRefGoogle Scholar
  20. 20.
    Berman E, Adams M, Duigou-Osterndorf R, et al. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood. 1991:77:818–25.PubMedGoogle Scholar
  21. 21.
    Bonadonna G, Valagussa P, Veronesi U. Results of ongoing clinical trials with adjuvant chemotherapy in operable breast cancer. In: Heuson JC, Mattheiem WH, Rozencweig M, eds. Breast Cancer Trends in Research and Treatment. New York, NY: Raven Press; 1976:239–58.Google Scholar
  22. 22.
    Fisher B, Carbone P, Economou SG, et al. L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: A report of early findings. N Engl J Med. 1975; 292:117–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976:294:405–10.PubMedCrossRefGoogle Scholar
  24. 24.
    Bonadonna G, Moliterni A, Zambetti M, et al. 30 years’ follow up of randomized studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ. 2005;330:217–23.PubMedCrossRefGoogle Scholar
  25. 25.
    Bonadonna G, Zambetti M, Moliterni A, et al. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer. J Clin Oncol. 2004;22:1614–20.PubMedCrossRefGoogle Scholar
  26. 26.
    Dang C, Hudis C. Adjuvant taxanes in the treatment of breast cancer: No longer at the tip of the iceberg. Clin Breast Cancer. 2006;7:51–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Poole CJ, Earl HM, Hiller L, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355:1851–62.PubMedCrossRefGoogle Scholar
  28. 28.
    Bonadonna G, Hortobagyi GN, Valagussa P. Individualized therapy of breast cancer: A dream or a reality? In: Bonadonna G, Hortobagyi GN, Valagussa P, eds. Textbook of Breast Cancer. A Clinical Guide to Therapy. 3rd ed. London New York: Taylor & Francis; 2006:395–99.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Pinuccia Valagussa
    • 1
  1. 1.Operations Office, Fondazione MichelangeloMilanoItaly

Personalised recommendations